Joost J. Oudejans

4.0k citations

68 papers · 3.0k indexed · h-index 34

Oncology top 2%
Pathology and Forensic Medicine top 0.5%
Immunology top 5%
Molecular Biology top 10%
Cancer Research top 5%

Co-authors: Chris J.L.M. Meijer Wim Vos Rosita L. ten Berge Danny F. Dukers Gert J. Ossenkoppele J. Alain Kummer Peter C. de Bruin P. J. van Diest
Topics: Lymphoma Diagnosis and Treatment (39 papers)Cell death mechanisms and regulation (11 papers)Viral-associated cancers and disorders (11 papers)
Cited by: Pathology and Forensic Medicine Gastroenterology Oncology
Journals: The Journal of Experimental Medicine Journal of Clinical Oncology Blood
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Joost J. Oudejans

68 papers receiving 3.0k citations

Peers

Countries citing papers authored by Joost J. Oudejans

Since Specialization

Citations

This map shows the geographic impact of Joost J. Oudejans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joost J. Oudejans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joost J. Oudejans more than expected).

Fields of papers citing papers by Joost J. Oudejans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joost J. Oudejans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joost J. Oudejans. The network helps show where Joost J. Oudejans may publish in the future.

Co-authorship network of co-authors of Joost J. Oudejans

This figure shows the co-authorship network connecting the top 25 collaborators of Joost J. Oudejans. A scholar is included among the top collaborators of Joost J. Oudejans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joost J. Oudejans. Joost J. Oudejans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A New and Validated Clinical Prognostic Model (EPI) for Enteropathy-Associated T-cell Lymphoma 2015 ·Clinical Cancer Research ·(unknown),Johannes Berkhof,(unknown),Michal Sieniawski,(unknown),Wieke H.M. Verbeek,Otto Visser,Joost J. Oudejans,Chris J.L.M. Meijer,Chris J. Mulder,Anne Lennard,Saskia A.G.M. Cillessen	18
2	Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification 2012 ·Breast Cancer Research and Treatment ·Robert Kornegoor,Cathy B. Moelans,Anoek H J Verschuur‐Maes,M. C. H. Hogenes,Peter C. de Bruin,Joost J. Oudejans,Luigi Marchionni,P. J. van Diest	45
3	Immunophenotyping of male breast cancer 2012 ·Histopathology ·Robert Kornegoor,Anoek H J Verschuur‐Maes,Horst Buerger,M. C. H. Hogenes,Peter C. de Bruin,Joost J. Oudejans,Bernd Hinrichs,P. J. van Diest	26
4	Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases 2012 ·Cancer ·(unknown),Cathy B. Moelans,Sybren L. Meijer,(unknown),Pieter Wesseling,Jelle Wesseling,Pieter J. Westenend,Joost Bart,Cornelis A. Seldenrijk,Irıs D. Nagtegaal,Joost J. Oudejans,Paul van der Valk,Carla H. van Gils,Elsken van der Wall,P. J. van Diest	73
5	Intensified alemtuzumab–CHOP therapy for peripheral T-cell lymphoma 2011 ·Annals of Oncology ·Hanneke C. Kluin‐Nelemans,Marinus van Marwijk Kooy,Pieternella J. Lugtenburg,Wim L.J. van Putten,Marleen Luten,Joost J. Oudejans,Gustaaf W. van Imhoff	55
6	Identification of genes putatively involved in the pathogenesis of diffuse large B‐cell lymphomas by integrative genomics 2008 ·Genes Chromosomes and Cancer ·Joost J. Oudejans,Wessel N. van Wieringen,Serge Smeets,Marianne Tijssen,(unknown),Chris J.L.M. Meijer,Gerrit A. Meijer,Mark A. van de Wiel,Bauke Ylstra	6
7	Expression of TNF‐receptor associated factor 2 correlates with poor progression‐free survival time in ABC‐like primary nodal diffuse large B‐cell lymphomas 2008 ·Histopathology ·Joost C. van Galen,Jettie J.F. Muris,(unknown),W Vos,G.J. Ossenkoppele,Chris J.L.M. Meijer,Joost J. Oudejans	6
8	Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T‐lymphocytes and preserved MHC class I antigen expression 2008 ·International Journal of Cancer ·Inge S. van Houdt,Berbel J.R. Sluijter,(unknown),Wim Vos,Tanja D. de Gruijl,Barbara G. Molenkamp,Alfons J.M. van den Eertwegh,Erik Hooijberg,Paul A.M. van Leeuwen,Chris J.L.M. Meijer,Joost J. Oudejans	106
9	Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in Refractory Celiac Disease 2007 ·Clinical Immunology ·Wieke H.M. Verbeek,Marije S. Goerres,B. Mary E. von Blomberg,Joost J. Oudejans,Petra E.T. Scholten,Muhammed Hadithi,Abdulbaqi Al–Toma,Marco W.J. Schreurs,Chris J. Mulder	100
10	Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma 2007 ·Digestive and Liver Disease ·Abdulbaqi Al–Toma,Wieke H.M. Verbeek,Otto Visser,(unknown),Joost J. Oudejans,Hanneke C. Kluin‐Nelemans,Chris J. Mulder,Peter C. Huijgens	62
11	High numbers of tumour‐infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis 2005 ·The Journal of Pathology ·Sietske A. Riemersma,Joost J. Oudejans,(unknown),Enno Dreef,Frans A. Prins,Patty M. Jansen,Maarten H. Vermeer,P Blok,(unknown),Jettie J.F. Muris,Ed Schuuring,Philip M. Kluin	48
12	FANCD2 Expression in Advanced Non–Small-Cell Lung Cancer and Response to Platinum-Based Chemotherapy 2005 ·Clinical Lung Cancer ·Miriam Ferrer,Simone W. Span,Barbara Vischioni,Joost J. Oudejans,P. J. van Diest,Johan P. de Winter,Giuseppe Giaccone,Frank A.E. Kruyt	14
13	Inhibition of Caspase 9 and Not Caspase 8 Mediated Apoptosis May Determine Clinical Response to Chemotherapy in Primary Nodal Diffuse Large B-Cell Lymphomas 2005 ·Cell Cycle ·Joost J. Oudejans,Jettie J.F. Muris,Chris J.L.M. Meijer	9
14	Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas 2003 ·Leukemia ·Jettie J.F. Muris,C J Meijer,Saskia A.G.M. Cillessen,W Vos,J. Alain Kummer,(unknown),M.J.J.T. Bogman,Marius MacKenzie,Natasha Jiwa,Matthijs L. Siegenbeek van Heukelom,G.J. Ossenkoppele,Joost J. Oudejans	77
15	ALK‐negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects–a review 2003 ·The Journal of Pathology ·Rosita L. ten Berge,Joost J. Oudejans,Gert J. Ossenkoppele,Chris J.L.M. Meijer	75
16	Apoptosis in B‐cell lymphomas and reactive lymphoid tissues always involves activation of caspase 3 as determined by a new in situ detection method 2002 ·The Journal of Pathology ·Danny F. Dukers,Joost J. Oudejans,Wim Vos,Rosita L. ten Berge,Chris J.L.M. Meijer	35
17	MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form 2001 ·Journal of Clinical Pathology ·Rosita L. ten Berge,Frank G.M. Snijdewint,Silvia von Mensdorff‐Pouilly,(unknown),Joost J. Oudejans,(unknown),Rein Willemze,Jo Hilgers,Chris J.L.M. Meijer	33
18	Rare Occurrence of Classical Hodgkin's Disease as a T Cell Lymphoma 2000 ·The Journal of Experimental Medicine ·Markus Müschen,Klaus Rajewsky,Andreas Bräuninger,Audrey Sylvia Baur,Joost J. Oudejans,Axel Roers,Martin‐Leo Hansmann,Ralf Küppers	155
19	Expression of Fas and Fas ligand in cutaneous B-cell lymphomas 1999 ·The Journal of Pathology ·(unknown),(unknown),Joost J. Oudejans,(unknown),(unknown),Rein Willemze	16
20	Enteropathy‐associated T‐cell lymphomas have a cytotoxic T‐cell phenotype 1997 ·Histopathology ·Peter C. de Bruin,C. E. Connolly,Joost J. Oudejans,J. Alain Kummer,(unknown),(unknown),C J Meijer	45

About Joost J. Oudejans

Joost J. Oudejans is a scholar working on Pathology and Forensic Medicine, Gastroenterology and Immunology, having authored 68 papers that have together received 3.0k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (39 papers), Cell death mechanisms and regulation (11 papers) and Viral-associated cancers and disorders (11 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.3k citations), Gastroenterology (372 citations) and Oncology (1.3k citations). Joost J. Oudejans has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Chris J.L.M. Meijer, Wim Vos, Rosita L. ten Berge, Danny F. Dukers, Gert J. Ossenkoppele, J. Alain Kummer, Peter C. de Bruin, P. J. van Diest, Chris J. Mulder and Abdulbaqi Al–Toma. Their work appears in journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact